A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Inclusion Criteria: Part A * Healthy male adults ≥18 and ≤50 years of age at screening. * Baseline FEV1 80-120% of predicted at Screening. * Oxygen saturation of ≥ 96% on room air as determined by pulse oximetry at Screening. * Screening laboratory tests within normal limits. Part B * Female and Male subjects who are ≥18 years of age and a confirmed diagnosis of CF. * FEV1 \>50% of predicted. * Oxygen saturation of ≥ 94% on room air as determined by pulse oximetry at Screening. * Stable CF pulmonary disease as judged by the Investigator. Exclusion Criteria: Part A * Any history of any form of lung disease or any systemic disease that may affect the lung or pulmonary function. * Former regular smoker or has smoked tobacco or cannabis products within the last 30 days. * Any history of any form of liver disease, renal disease, cardiac disease, hematologic disease, neurologic disease, atopy or any chronic condition. * Participation in one or more healthy subject studies within the prior 3 months. Part B * Participation in a clinical trial involving receipt of an investigational product within the 30 days prior to screening. * Female subjects who are pregnant (a negative serum pregnancy test must be demonstrated at screening), have a positive pregnancy test, are lactating or who plan to become pregnant within 90 days after dosing. * Subjects requiring supplemental oxygen. * Hemoptysis of \>5 mL within 12 weeks of screening. * Listed for organ transplantation.